Sandro Feriozzi

4.7k total citations
73 papers, 1.3k citations indexed

About

Sandro Feriozzi is a scholar working on Physiology, Nephrology and Pathology and Forensic Medicine. According to data from OpenAlex, Sandro Feriozzi has authored 73 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Physiology, 26 papers in Nephrology and 19 papers in Pathology and Forensic Medicine. Recurrent topics in Sandro Feriozzi's work include Lysosomal Storage Disorders Research (37 papers), Renal Diseases and Glomerulopathies (16 papers) and Biomedical Research and Pathophysiology (14 papers). Sandro Feriozzi is often cited by papers focused on Lysosomal Storage Disorders Research (37 papers), Renal Diseases and Glomerulopathies (16 papers) and Biomedical Research and Pathophysiology (14 papers). Sandro Feriozzi collaborates with scholars based in Italy, United States and Argentina. Sandro Feriozzi's co-authors include Paula Rozenfeld, Gere Sunder‐Plassmann, Stephen Waldek, Markus Cybulla, Michael L. West, Andreas Schwarting, Antonio Pisani, Derralynn Hughes, Alessandro Pierucci and Giulio A. Cinotti and has published in prestigious journals such as New England Journal of Medicine, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

Sandro Feriozzi

66 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandro Feriozzi Italy 20 899 349 315 304 262 73 1.3k
S N Iyer United States 9 222 0.2× 172 0.5× 151 0.5× 139 0.5× 78 0.3× 9 1.3k
Fokko van der Woude Germany 12 292 0.3× 53 0.2× 186 0.6× 207 0.7× 64 0.2× 23 1.1k
Pascale de Lonlay France 26 199 0.2× 216 0.6× 92 0.3× 28 0.1× 173 0.7× 71 2.0k
P Lohse Germany 27 140 0.2× 148 0.4× 81 0.3× 51 0.2× 101 0.4× 57 1.4k
Minoru Tahara Japan 14 532 0.6× 437 1.3× 159 0.5× 6 0.0× 123 0.5× 26 1.2k
P. Kaminsky France 19 159 0.2× 88 0.3× 244 0.8× 33 0.1× 53 0.2× 78 1.0k
Sanae Teshigawara Japan 16 167 0.2× 280 0.8× 53 0.2× 62 0.2× 37 0.1× 30 934
Esmeralda Martins Portugal 20 226 0.3× 58 0.2× 219 0.7× 12 0.0× 29 0.1× 77 988
H. Ogier France 21 293 0.3× 52 0.1× 207 0.7× 47 0.2× 21 0.1× 55 1.4k
Zachary Oaks United States 15 87 0.1× 173 0.5× 371 1.2× 29 0.1× 78 0.3× 20 1.0k

Countries citing papers authored by Sandro Feriozzi

Since Specialization
Citations

This map shows the geographic impact of Sandro Feriozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandro Feriozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandro Feriozzi more than expected).

Fields of papers citing papers by Sandro Feriozzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandro Feriozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandro Feriozzi. The network helps show where Sandro Feriozzi may publish in the future.

Co-authorship network of co-authors of Sandro Feriozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Sandro Feriozzi. A scholar is included among the top collaborators of Sandro Feriozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandro Feriozzi. Sandro Feriozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jovanović, Ana, Eve Miller‐Hodges, Obaro Evuarherhe, et al.. (2025). Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review. Journal of Clinical Medicine. 14(14). 5131–5131. 2 indexed citations
2.
Rozenfeld, Paula, Sandro Feriozzi, & Fabian Braun. (2024). The role of tubular cells in the pathogenesis of Fabry nephropathy. Frontiers in Cardiovascular Medicine. 11. 1386042–1386042. 2 indexed citations
3.
Feriozzi, Sandro, et al.. (2024). Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data. Drug Design Development and Therapy. Volume 18. 1083–1101. 5 indexed citations
4.
Kirchmayer, Ursula, Claudia Marino, Sandro Feriozzi, et al.. (2024). Drug utilization in patients starting haemodialysis with a focus on cardiovascular and antidiabetic medications: an epidemiological study in the Lazio region (Italy), 2016–2020. BMC Nephrology. 25(1). 98–98. 1 indexed citations
5.
Baragetti, Ivano, Lucia Del Vecchio, Francesca Ferrario, et al.. (2024). The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort. Journal of Nephrology. 38(1). 225–234. 3 indexed citations
6.
Bondar, Constanza, et al.. (2024). Pathogenic pathways of renal damage in Fabry nephropathy: interplay between immune cell infiltration, apoptosis and fibrosis. Journal of Nephrology. 37(3). 625–634. 1 indexed citations
7.
Consolato, Francesco, Maurizio De Fusco, Céline Schaeffer, et al.. (2022). α-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response. Molecular Genetics and Metabolism Reports. 33. 100926–100926. 18 indexed citations
8.
Bellasi, Antonio, et al.. (2021). Effects of secondary hyperparathyroidism treatment on hemoglobin levels and erythropoietin doses in hemodialysis patients. INFM-OAR (INFN Catania). 5(3). 88–94. 1 indexed citations
9.
Ranalli, Teresa Valentina, et al.. (2020). Rapid progressive anti-GBM glomerulonephritis with multiple auto-antibodies. Journal of Nephropathology. 9(3). e30–e30. 2 indexed citations
10.
Capuano, Ivana, Carlo Garofalo, Pasquale Buonanno, et al.. (2019). Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019. Journal of Nephrology. 33(3). 569–581. 16 indexed citations
11.
Rozenfeld, Paula, et al.. (2019). Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. Molecular Genetics and Metabolism. 129(2). 132–141. 32 indexed citations
12.
Quintaliani, Giuseppe, Marina Di Luca, Anteo Di Napoli, et al.. (2017). [Census of the renal and dialysis units by Italian Society of Nephrology: structure and organization for renal patient assistance in Italy (2014-2015)].. PubMed. 33(5). 1 indexed citations
13.
Cocozza, Sirio, Camilla Russo, Antonio Pisani, et al.. (2017). Redefining the Pulvinar Sign in Fabry Disease. American Journal of Neuroradiology. 38(12). 2264–2269. 28 indexed citations
14.
Matafora, Vittoria, Amerigo Beneduci, Pietro Anastasio, et al.. (2015). Early markers of Fabry disease revealed by proteomics. Molecular BioSystems. 11(6). 1543–1551. 60 indexed citations
15.
Sharma, Aashish, José J. Zaragoza, Gianluca Villa, et al.. (2015). Fabry’s disease: an example of cardiorenal syndrome type 5. Heart Failure Reviews. 20(6). 689–708. 11 indexed citations
16.
Polci, Rosaria & Sandro Feriozzi. (2011). [Immunotherapy mechanisms in glomerulonephritis].. PubMed. 28(6). 612–21. 1 indexed citations
17.
Feriozzi, Sandro, Andreas Schwarting, Gere Sunder‐Plassmann, Michael L. West, & Markus Cybulla. (2008). Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease. American Journal of Nephrology. 29(5). 353–361. 53 indexed citations
18.
Feriozzi, Sandro, et al.. (2006). Renal Oncocytoma Associated with Necrotizing Glomerulonephritis. Renal Failure. 28(2). 181–183. 4 indexed citations
19.
Schwarting, Andreas, Sandro Feriozzi, Michael Møller Bech, et al.. (2005). Agalsidase alfa prevents the decline in renal function in patients with Fabry disease.. UCL Discovery (University College London). 1 indexed citations
20.
Pierucci, Alessandro, Bianca M. Simonetti, Gabriella Pecci, et al.. (1989). Improvement of Renal Function with Selective Thromboxane Antagonism in Lupus Nephritis. New England Journal of Medicine. 320(7). 421–425. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S N Iyer Breakdown of academic impact, for papers by Fokko van der Woude Breakdown of academic impact, for papers by Pascale de Lonlay Breakdown of academic impact, for papers by P Lohse Breakdown of academic impact, for papers by Minoru Tahara Breakdown of academic impact, for papers by P. Kaminsky Breakdown of academic impact, for papers by Sanae Teshigawara Breakdown of academic impact, for papers by Esmeralda Martins Breakdown of academic impact, for papers by H. Ogier Breakdown of academic impact, for papers by Zachary Oaks
Rankless by CCL
2026